Skip to main content

Table 3 Outcomes stratified by Visual Acuity at presetation

From: Treatment outcomes of retinal vein occlusion in clinical practice in Nepal

  CRVO (n = 39) BRVO (n = 60) p value
Eyes with presenting VA ≤0.3 logMAR
Eyes, n (%) 4 (10) 12 (20) 0.05
Baseline VA logMAR, mean (SD) 0.28 (0.05) 0.18 (0.13) 0.5
Final VA logMAR, mean (SD)* 0.54 (0.83) 0.22 (0.25) 0.71
Change VA logMAR*,
mean (95% CI)
0.26
(−1.04, 1.57)
0.03
(−0.13, 0.2)
0.61
Baseline CST μm, mean (SD) 423 (152) 330 (102) 0.31
Final CST μm, mean (SD)* 268 (50) 230 (110) 0.46
Change CST μm*,
mean (95% CI)
− 155
(− 390, 80)
− 79
(− 206, 48)
0.42
Injectionsα, median (Q1, Q3) 0.5 (0, 1.5) 0 (0, 1.2) 0.94
Additional Macular Laser, n 0 0 1
Additional Triamcinolone, n 0 0 1
Additional PRP, n 1 5 1
Eyes with presenting VA ≤0.3 logMAR
Eyes, n (%) 35 (90) 48 (80)  
Baseline VA logMAR, mean (SD) 1.22 (0.57) 0.89 (0.34) 0.02
Final VA logMAR, mean (SD)* 0.97 (0.74) 0.44 (0.42) < 0.001
Change VA logMAR*,
mean (95% CI)
−0.26
(−0.49, −0.03)
−0.44
(−0.57, − 0.32)
0.15
Baseline CST μm, mean (SD) 531 (218) 449 (153) 0.07
Final CST μm, mean (SD)* 355 (168) 291 (137) 0.12
Change CST μm*,
mean (95% CI)
− 188
(− 294, −82)
−120
(−206, −34)
0.30
Injectionsα, median (Q1, Q3) 2 (1, 3) 2 (1, 3) 0.72
Additional Macular Laser, n 0 2 0.5
Additional Triamcinolone, n 2 2 1
Additional PRP/Sectoral Laser, n 15 10 0.05
  1. n Number, VA Visual Acuity, SD Standard Deviation, CI Confidence Interval, CST Central Subfield Thickness, Q1 First Quantile, Q3 Third Quantile, PRP Panretinal photocoagulation, * Last observation carried forward for lost to follow-up, α Number of bevacizumab injections
\